Anthony Hunter MD
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Assistant Professor, Emory University School of Medicine, Winship Cancer Institute
Join to View Full Profile
1365 Clifton Rd NEAtlanta, GA 30322
Phone+1 404-778-1900
Dr. Hunter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Anthony Hunter is a hematologist based in Atlanta, GA, with subspecialties in hematologic oncology and myeloproliferative disorder hematology-oncology. He completed his fellowship in hematology and medical oncology at the University of South Florida, and his residency in internal medicine at Emory University School of Medicine, where he is now an assistant professor. Dr. Hunter has research experience in leukemia and has published several articles in high-profile journals such as JAMA Oncology and Blood. His works focus on drug development and treatment strategies for conditions like myeloproliferative neoplasms and myelodysplastic syndromes.
Education & Training
University of South Florida Morsani College of Medicine/Moffitt Cancer Center/Tampa General HospitalFellowship, Hematology and Medical Oncology, 2017 - 2020
Emory University School of MedicineResidency, Internal Medicine, 2014 - 2017
Medical College of WisconsinClass of 2014
Certifications & Licensure
GA State Medical License 2020 - 2027
FL State Medical License 2017 - 2021
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Risk factors, behaviors, and adverse health outcomes of financial toxicity in adult chronic myeloid leukemia survivors: a theory-based structural equation model.Ruiqi Jin, Sudeshna Paul, Sarah M Belcher, Jinbing Bai, Ilana Graetz
Supportive Care in Cancer. 2025-06-05 - 1 citationsSOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.Michael J Hochman, Colin A Vale, Anthony M Hunter
Clinical Lymphoma, Myeloma & Leukemia. 2025-04-01 - 8 citationsOlverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.Elias Jabbour, Vivian G Oehler, Paul B Koller, Omer Jamy, Elza Lomaia
JAMA Oncology. 2025-01-01
Abstracts/Posters
- Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell TransplantationAnthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Effects of the Therapeutic Armamentarium on Survival and Time to Next Treatment in CMML Subtypes: An International Analysis of 950 Cases Coordinated By the AGMT Study ...Anthony M. Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic LeukemiaAnthony Hunter, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- CSF3R Mutations Are Exceedingly Rare Genetic Events Associated with Inferior Survival and Sensitivity to Ruxolitinib across Myeloid Malignancies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Press Mentions
Q&A: Guideline-Based Care Often Missing in Polycythemia VeraMay 19th, 2025
A Legacy of TyrosineMay 11th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
